Cesium Pioneers
New Research on Cesium-131 Presented at ASTRO
With over ten years of data on Cesium-131, researchers continue to study its value in powering modern brachytherapy. ASTRO 2020 showcased multiple new e-posters and papers that can now be easily accessed online. A Matched Pair Analysis Of...
All News
New Research on Cesium-131 Presented at ASTRO
With over ten years of data on Cesium-131, researchers continue to study its value in powering modern brachytherapy. ASTRO 2020 showcased multiple new e-posters and papers that can now be easily accessed online. A Matched Pair Analysis Of Clinical Outcomes...
When is a change worth the trouble for brachytherapy?
Gains in engagement, conformal coverage, seamless logistics, planning, and procedural efficiency drive Wisconsin brachytherapy program’s transition to Cesium Blu™.
The Big Reason Why One Team Switched to Cesium Blu Brachytherapy
“The potential to smooth out our workflow and increase our potential candidate pool for the procedure given the ability to do brachytherapy with Cesium Blu prior to EBRT is a compelling motivation for adding it to our prostate cancer treatment arsenal,”- Dr. Bobby...
Dr. Peter Orio Showcases the Elegance and Simplicity of Brachytherapy for Prostate Cancer
Photo curtesy of The Boston Herald. Boston Herald Reporter Alexi Cohan recently joined Dr. Peter Orio on the “front lines” in order to learn more about brachytherapy for prostate cancer treatment. This article details the brachytherapy procedure process and the...
Transitioning isotopes for prostate brachytherapy: Dr. Bernard Taylor, Texas Oncology
Transition concerns should not stop you from adding Cesium to your prostate brachytherapy practice. With a thoughtful approach to planning and the right support, you can seamlessly upgrade your prostate brachytherapy to the power of Cesium.
Prostate Cancer Research Institute: “The Importance of Knowing About All of Your Prostate Cancer Treatment Options”
“I urge newly diagnosed men to see a range of specialists before selecting treatment. After talking to a urologist, they should make independent appointments with a radiation oncologist, a medical oncologist, and a brachytherapist to ensure that they become fully...
Patients & Families
Find a Doctor Near You
A diagnosis is just the first step toward treating your cancer. We are here to help you make an informed treatment decision with your doctor so you can begin living your life again.
Advantageous biological effect, Cesium-131’s short half-life, and new shielded or dynamically modulated sources: Dr. Mark Rivard’s thoughts on brachytherapy from ABS 2018
As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types.
Study Shows Significantly Improved Survival Rate of Cervical Cancer Patients after Receiving Brachytherapy and EBRT
The International Journal of Radiation Oncology recently published a study titled Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer.
The value of Cesium for brachytherapy treatment lies in its short half-life for Dr. R. Alex Hsi
Dr. R. Alex Hsi is a Radiation Oncologist at the Peninsula Cancer Center in Poulsbo, Washington. As a practitioner of various prostate radiation treatments like external beam radiation and stereotactic body radiation...
Nearly out of treatment options, Cesium-131 brachytherapy saved Barbara’s life
Dr. John Sheldon brought his experience with brachytherapy to bear with a targeted treatment for Barbie after her cervical cancer returned in 2015.
Biological effectiveness dose and convenience: Why Cesium-131 is the LDR brachytherapy isotope of choice for Dr. Bradley Prestidge.
Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the American Brachytherapy Society 2018 Annual Meeting, Dr. Prestidge shared with us his opinion on brachytherapy’s top...
New long-term data show brachytherapy boost improves freedom from biochemical failure outcomes for T3 high-risk prostate cancer by more than eight percent
In a new study, radiation oncologists find that DR-BT is not only feasible, but also highly effective in men with cT3a and cT3b high-risk prostate cancer.
Dr. John Sylvester Explores the Many Advantages of the Prostate Brachytherapy Procedure Over Surgery at ABS 2018
According to Dr. Sylvester, brachytherapy provides many advantages over surgery for prostate cancer treatment. This underscores the importance of prostate cancer patients becoming aware of brachytherapy as a treatment option.
Three recent peer-reviewed publications reinforce the value of brachytherapy as a treatment for prostate cancer
The past 12 to 18 months have seen remarkable new scientific evidence come to light regarding the attributes and benefits of brachytherapy, including Cesium-131, for prostate cancer treatment.
Our favorite prostate cancer support resources: 2018 edition
As the importance of patient involvement in determining their optimal post-treatment quality of life, these organizations educate and support the men and families affected by prostate cancer.
Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates
“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.
Newsweek: “Prostate cancer is often diagnosed too late.”
Prostate cancer is one of the deadliest and most common cancers among men today. An article written by Melissa Matthews was recently published by Newsweek revealing that late detection plays a key role in why prostate cancer is so fatal.
Dr. Brian Moran: Brachytherapy: An Innovative Disruptor
Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field at ABS 2018.
ABS 2018 Insights: Science, Improving Your Practice, Social Time & Thanks
With the 2018 edition of the American Brachytherapy Annual Meeting in the books, it is fitting to take a few minutes and highlight our top ABS 2018 Insights. The clinical experience with Cesium-131 continues to build: Dr. Manuj Agarwal of the University of Maryland...
Prostate Cancer News Today: “Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality”
“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.” The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was...
Medpage Today: “EBRT with Brachytherapy Matches Surgery for Prostate Ca”
Worse survival without [brachytherapy] boost in high-risk patients At long last, the mounting scientific evidence for the value of brachytherapy for prostate cancer treatment is starting to generate more awareness among the care community and associated industry...
Sharpening the focus on focal therapy for prostate cancer treatment
To the benefit of patients and urologists worldwide, focal therapy for prostate cancer bridges the sizable gap between active surveillance and radical prostatectomy. Its ability to provide effective disease control, minimize the potential for chronic incontinence and...
Brachytherapy and Radical Prostatectomy Show Similar Survival Results in High-Risk Localized Prostate Cancer
There is a growing amount of evidence that brachytherapy’s role as a prostate cancer treatment modality should not be limited to low-risk cases, but should also include patients with higher risk disease. The Journal of Clinical Oncology recently reported on an...
New study reports that combination treatment with brachytherapy yields significantly better outcomes for men with aggressive prostate cancer
Earlier this month, a retrospective study of prostate cancer patients with Gleason scores of 9-10 published online by the Journal of the American Medical Association concluded the following: “Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT...
ASCENDE-RT: A One-of-a-Kind Breakthrough Study
Brachytherapy treatment for prostate cancer is not a new venture to many clinicians. However, new, groundbreaking data is here to shed light on how brachytherapy is significantly improving patient outcomes. ASCENDE-RT is the first ever controlled, randomized trial to...
UVA Today: “A Gold-Standard Cancer Treatment Is In Decline, And Money May Be Why”
Dr. Timothy Showalter, a radiation oncologist, led the study on why a potentially life-saving treatment for cervical cancer was being less utilized. (Photo by Josh Barney, UVA Health System) “The evidence is clear: Cervical cancer is best treated with brachytherapy, a...